C
Constance M. Yuan
Researcher at National Institutes of Health
Publications - 133
Citations - 10629
Constance M. Yuan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Minimal residual disease & Multiple myeloma. The author has an hindex of 35, co-authored 133 publications receiving 8169 citations.
Papers
More filters
Journal ArticleDOI
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Journal ArticleDOI
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry,Nirali N. Shah,Rimas J. Orentas,Maryalice Stetler-Stevenson,Constance M. Yuan,Sneha Ramakrishna,Pamela L. Wolters,Staci Martin,Cindy Delbrook,Bonnie Yates,Haneen Shalabi,Thomas J. Fountaine,Jack F. Shern,Robbie G. Majzner,David F. Stroncek,Marianna Sabatino,Yang Feng,Dimiter S. Dimitrov,Ling Zhang,Sang M. Nguyen,Haiying Qin,Boro Dropulic,Daniel W. Lee,Crystal L. Mackall +23 more
TL;DR: These results are the first to establish the clinical activity of a CD22-CAR in B-all, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
Journal ArticleDOI
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu,Patricia Pérez-Galán,Delong Liu,Angelique Biancotto,Stefania Pittaluga,Berengere Vire,Federica Gibellini,Ndegwa Njuguna,Elinor Lee,Lawrence S. Stennett,Nalini Raghavachari,Poching Liu,J. Philip McCoy,Mark Raffeld,Maryalice Stetler-Stevenson,Constance M. Yuan,Richard M. Sherry,Diane C. Arthur,Irina Maric,Therese White,Gerald E. Marti,Peter J. Munson,Wyndham H. Wilson,Adrian Wiestner +23 more
TL;DR: The disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL are identified.
Journal ArticleDOI
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso,Daniel W. Lee,Nirali N. Shah,Maryalice Stetler-Stevenson,Constance M. Yuan,Ira Pastan,Dimiter S. Dimitrov,Richard A. Morgan,David J. FitzGerald,David M. Barrett,Alan S. Wayne,Alan S. Wayne,Crystal L. Mackall,Rimas J. Orentas +13 more
TL;DR: It is concluded that second-generation m971 mAb-derived anti-CD22 CARs are promising novel therapeutics that should be tested in BCP-ALL.
Journal ArticleDOI
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno,Irina Maric,Steven Hartman,Jeremy J. Rose,Michael Wang,Norris Lam,Maryalice Stetler-Stevenson,Dalia A. Salem,Constance M. Yuan,Steven Z. Pavletic,Jennifer A. Kanakry,Syed Abbas Ali,Lekha Mikkilineni,Steven A. Feldman,David F. Stroncek,Brenna Hansen,Judith Lawrence,Rashmika Patel,Frances T. Hakim,Ronald E. Gress,James N. Kochenderfer +20 more
TL;DR: CAR-BCMA T cells had substantial activity against heavily treated relapsed/refractory MM and should encourage additional development of CAR T-cell therapies for MM.